Internal Medicine, Endocrinology, Diabetes, & Metabolism · Webster, TX
NPI
1306933957
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
18833 Eastfield Dr
Webster, TX, 77598
Phone (713) 442-4300
Groups this clinician bills Medicare through
Medicare paid, 2024
$1,726
70 services
Medicare patients, 2024
19
Average age 69
Drug cost, 2024
$2.4M
8,651 prescriptions
Company payments, 2024
$133
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tom M Thomas was code 99214 (office e&m - established), 18 times for 13 patients. In total Tom M Thomas billed 70 services in 15 codes, and Medicare paid $1,726.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 18 | 13 | $56.71 | $1,021 |
| 36415 Venipuncture Blood Collection | Office | 15 | 11 | $7.08 | $106 |
By year: 2022 $1,261 for 23 services; 2023 $1,388 for 44 services; 2024 $1,726 for 70 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 15 | 11 | $7.08 | $106 |
Medicare prescription drug claims, 2024
In 2024, the drug Tom M Thomas prescribed most often to Medicare patients was Levothyroxine Sodium, with 696 prescriptions and refills. In total Tom M Thomas wrote 8,651 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 696 | 1,938 | 197 | $2,506 |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 480 | 753 | 99 | $503K |
| Atorvastatin Calcium Generic | 477 | 1,293 | 144 | $14K |
| Novolog Flexpen Insulin Aspart | 464 | 969 | 160 | $93K |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 449 | 996 | 170 | $38K |
| Jardiance Empagliflozin | 397 | 534 | 80 | $306K |
| Metformin Hcl Generic | 360 | 949 | 114 | $4,815 |
| Ozempic Semaglutide | 357 | 458 | 75 | $414K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 342 | 695 | 103 | $200K |
| Lisinopril Generic | 268 | 733 | 89 | $3,643 |
| Gabapentin Generic | 206 | 377 | 56 | $1,608 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 205 | 394 | 72 | $29K |
| Amlodipine Besylate Generic | 186 | 496 | 62 | $1,656 |
| Alendronate Sodium Generic | 174 | 468 | 54 | $3,840 |
| Losartan Potassium Generic | 160 | 465 | 54 | $4,583 |
Brand drugs: 3,242 claims; generic drugs: 4,661 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Tom M Thomas $133 ($133 in general payments such as food, travel and fees) from 2 companies. The largest payer was CeQur Corporation with $107.
| Company | Payments | Amount |
|---|---|---|
| CeQur Corporation | 1 | $107 |
| Beta Bionics, Inc. BBNX | 1 | $26.22 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.